CAMBRIDGE, Mass.--(BUSINESS WIRE)--PixarBio Corporation today announced that its CEO Frank Reynolds will be discussing breakthrough non-opiate pain treatments at the 8th Annual OneMedForum held at the Marriot Marquis in San Francisco, CA.
PixarBio’s presentation is scheduled for:
|Date:||Monday, January 12, 2015|
|San Francisco Marriot Marquis|
|780 Mission Street, San Francisco, CA 94103|
“Patient and regulatory demand for novel, non-opiate pain treatments is escalating. The FDA’s concerns around long-term use of opiates and Tylenol are clear. PixarBio responded in our labs by developing a novel non-opiate drug delivery system. Days, weeks, or months of targeted non-opiate pain relief will change the practice of medicine. PixarBio will achieve significant milestones in 2015 establishing our cGMP manufacturing facility to support human studies in 2016 and FDA approval in 2017”, said PixarBio CEO Frank Reynolds.
Next to the JP Morgan Healthcare Investor Conference, the industry’s largest annual healthcare investor conference, and Biotech Showcase, OneMedForum is one of the three investor conferences held in San Francisco every January that connect private and public biotechnology and life sciences companies with investors and pharmaceutical executives. This year’s event will feature presentations from almost 100 innovative growth companies.
About PixarBio Corporation
PixarBio Corporation is developing a targeted delivery platform to treat pain, epilepsy, Parkinson’s disease, and spinal cord injury. Cofounded by Frank Reynolds, MIT’s Dr. Robert S. Langer and Katrin Holzhaus, PixarBio is focused on commercializing the targeted delivery system for acute and chronic neurological conditions. For more information visit www.pixarbio.com.